TMCnet News
Enlivex Therapeutics To Present At The 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.Nes-Ziona, Israel, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation at the 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., being held at the Lotte New York Palace Hotel in New York. The presentation is scheduled for September 9th 2019 at 2:10pm local time. To join the live webcast, please click http://wsw.com/webcast/hcw5/enlv/ and register prior to the presentation time. ALLOCETRATM by Enlivex was designed to provide a novel immunotherapy mechanism of action that trgets life-threatening clinical indications that are defined as “unmet medical needs”, including prevention or treatment of complications associated with bone marrow transplantations (BMT) and/or hematopoietic stem cell transplantations (HSCT); organ dysfunction and acute multiple organ failure associated with Sepsis; and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing. For more information about the 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., visit http://www.rodmanevents.com/ ABOUT ENLIVEX ENLIVEX CONTACT: |